Top

Published in:

Open Access 01-12-2024 | Cystectomy | Research

Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study

Authors: Jiayuan Zhao, Dan Wang, Ruojiao Wang, Yonglan He, Congwei Jia, Lingya Pan, Shuiqing Ma, Ming Wu, Weidi Wang, Xinghan Cheng, Junjun Yang, Yang Xiang

Published in: Journal of Ovarian Research | Issue 1/2024

Abstract

Objective

To describe the characteristics of children and adolescents with borderline ovarian tumors (BOTs) and evaluate the efficacy and safety of fertility-sparing surgery (FSS) in these patients.

Methods

Patients with BOTs younger than 20 years who underwent FSS were included in this study.

Results

A total of 34 patients were included, with a median patient age of 17 (range, 3–19) years; 97.1% (33/34) of cases occurred after menarche. Of the patients, 82.4% had mucinous borderline tumors (MBOTs), 14.7% had serous borderline tumors (SBOTs), and 2.9% had seromucinous borderline tumor (SMBOT). The median tumor size was 20.4 (range, 8–40)cm. All patients were at International Federation of Gynecology and Obstetrics stage I and all underwent FSS: cystectomy (unilateral ovarian cystectomy, UC, 14/34, 41.2% and bilateral ovarian cystectomy, BC, 1/34, 2.9%), unilateral salpingo-oophorectomy (USO; 18/34; 52.9%), or USO + contralateral ovarian cystectomy (1/34; 2.9%). The median follow-up time was 65 (range, 10–148) months. Recurrence was experienced by 10 of the 34 patients (29.4%). One patient with SBOT experienced progression to low-grade serous carcinoma after the third relapse. Two patients had a total of four pregnancies, resulting in three live births. The recurrence rate of UC was significantly higher in MBOTs than in USO (p = 0.005). The 5-year disease-free survival rate was 67.1%, and the 5-year overall survival rate was 100%.

Conclusions

Fertility-sparing surgery is feasible and safe for children and adolescents with BOTs. For patients with MBOTs, USO is recommended to lower the risk of recurrence.

Cass DL, Hawkins E, Brandt ML, et al. Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg. 2001;36(5):693–9. https://doi.org/10.1053/jpsu.2001.22939.CrossRefPubMed

Morowitz M, Huff D, Von Allmen D. Epithelial ovarian tumors in children: A retrospective analysis. J Pediatr Surg. 2003;38(3):331–5. https://doi.org/10.1053/jpsu.2003.50103.CrossRefPubMed

Brown MF, Hebra A, McGeehin K, Ross AJ. Ovarian masses in children: A review of 91 cases of malignant and benign masses. J Pediatr Surg. 1993;28(7):930–2. https://doi.org/10.1016/0022-3468(93)90700-U.CrossRefPubMed

Massicot R, Rousseau V, Darwish AA, Sauvat F, Jaubert F, Nihoul-Fékété C. Serous and seromucinous infantile ovarian cystadenomas—A study of 42 cases. Eur J Obstet Gynecol Reprod Biol. 2009;142(1):64–7. https://doi.org/10.1016/j.ejogrb.2008.09.007.CrossRefPubMed

Xu M, Wang B, Shi Y. Borderline ovarian tumor in the pediatric and adolescent population: a clinopathologic analysis of fourteen cases. Int J Clin Exp Pathol. 2020;13(5):1053–9.PubMedPubMedCentral

Adolescent and young adult health. Accessed February 5, 2024. https://www.who.int/news-room/fact-sheets/detail/adolescents-health-risks-and-solutions.

Harter P, Gershenson D, Lhomme C, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2014;24(9 Suppl 3):S5–8. https://doi.org/10.1097/IGC.0000000000000282.CrossRef

Colombo N, Sessa C, du Bois A, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease††These consensus statements were developed by the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO) and are published jointly in the Annals of Oncology and the International Journal of Gynecological Cancer. The two societies nominated participants who attended the consensus conference and co-authored the final manuscript. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062.CrossRefPubMed

Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012;13(3):e103–15. https://doi.org/10.1016/S1470-2045(11)70288-1.CrossRefPubMed

10.

Childress KJ, Patil NM, Muscal JA, Dietrich JE, Venkatramani R. Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. J Pediatr Adolesc Gynecol. 2018;31(1):48–54. https://doi.org/10.1016/j.jpag.2017.09.001.CrossRefPubMed

11.

Song T, Choi CH, Lee YY, et al. Pediatric borderline ovarian tumors: a retrospective analysis. J Pediatr Surg. 2010;45(10):1955–60. https://doi.org/10.1016/j.jpedsurg.2010.06.012.CrossRefPubMed

12.

Tsikouras P, Liberis V, Galazios G, et al. A retrospective analysis of twenty-eight borderline ovarian tumours in adolescent girls. Eur J Gynaecol Oncol. 2009;30(1):49–53.PubMed

13.

Omidimorad A, Nazari M, Bahmanziari N, et al. Priority strategic directions in adolescent health in Iran based on the WHO’s Global Accelerated Action for the Health of Adolescents. Int J Adolesc Med Health. 2023;35(4):313–21. https://doi.org/10.1515/ijamh-2023-0023.CrossRefPubMed

14.

Flicek KT, VanBuren W, Dudiak K, et al. Borderline epithelial ovarian tumors: what the radiologist should know. Abdom Radiol. 2021;46(6):2350–66. https://doi.org/10.1007/s00261-020-02688-z.

15.

Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4. https://doi.org/10.1016/j.ygyno.2014.04.013.CrossRefPubMed

16.

Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch Int J Pathol. 2017;470(2):125–42. https://doi.org/10.1007/s00428-016-2040-8.CrossRef

17.

Yokoyama Y, Moriya T, Takano T, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer. 2006;94(11):1586–91. https://doi.org/10.1038/sj.bjc.6603139.CrossRefPubMedPubMedCentral

18.

Morotti M, Menada MV, Gillott DJ, Venturini PL, Ferrero S. The preoperative diagnosis of borderline ovarian tumors: a review of current literature. Arch Gynecol Obstet. 2012;285(4):1103–12. https://doi.org/10.1007/s00404-011-2194-1.CrossRefPubMed

19.

Yazbek J, Aslam N, Tailor A, Hillaby K, Raju KS, Jurkovic D. A comparative study of the risk of malignancy index and the ovarian crescent sign for the diagnosis of invasive ovarian cancer. Ultrasound Obstet Gynecol. 2006;28(3):320–4. https://doi.org/10.1002/uog.2842.CrossRefPubMed

20.

Van Holsbeke C, Van Belle V, Leone FPG, et al. Prospective external validation of the ‘ovarian crescent sign’ as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol. 2010;36(1):81–7. https://doi.org/10.1002/uog.7625.CrossRefPubMed

21.

Hillaby K, Aslam N, Salim R, Lawrence A, Raju KS, Jurkovic D. The value of detection of normal ovarian tissue (the ‘ovarian crescent sign’) in the differential diagnosis of adnexal masses. Ultrasound Obstet Gynecol. 2004;23(1):63–7. https://doi.org/10.1002/uog.946.CrossRefPubMed

22.

Yazbek J, Raju KS, Ben-Nagi J, Holland T, Hillaby K, Jurkovic D. Accuracy of ultrasound subjective ‘pattern recognition’ for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2007;29(5):489–95. https://doi.org/10.1002/uog.4002.CrossRefPubMed

23.

Flicek KT, VanBuren W, Dudiak K, et al. Borderline epithelial ovarian tumors: what the radiologist should know. Abdom Radiol. 2021;46(6):2350–66. https://doi.org/10.1007/s00261-020-02688-z.CrossRef

24.

Tsuboyama T, Sato K, Ota T, et al. MRI of Borderline Epithelial Ovarian Tumors: Pathologic Correlation and Diagnostic Challenges. Radiogr Rev Publ Radiol Soc N Am Inc. 2022;42(7):2095–111. https://doi.org/10.1148/rg.220068.CrossRef

25.

Kaga T, Kato H, Hatano Y, et al. Can MRI features differentiate ovarian mucinous carcinoma from mucinous borderline tumor? Eur J Radiol. 2020;132:109281. https://doi.org/10.1016/j.ejrad.2020.109281s.CrossRefPubMed

26.

Pecorino B, Laganà AS, Mereu L, et al. Evaluation of Borderline Ovarian Tumor Recurrence Rate after Surgery with or without Fertility-Sparing Approach: Results of a Retrospective Analysis. Healthcare. 2023;11(13):1922. https://doi.org/10.3390/healthcare11131922.CrossRefPubMedPubMedCentral

27.

Ozenne A, De Berti M, Body G, et al. Risk Factors for Recurrence of Borderline Ovarian Tumours after Conservative Surgery and Impact on Fertility: A Multicentre Study by the Francogyn Group. J Clin Med. 2022;11(13):3645. https://doi.org/10.3390/jcm11133645.CrossRefPubMedPubMedCentral

28.

Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril. 2003;79(5):1216–21. https://doi.org/10.1016/S0015-0282(03)00160-2.CrossRefPubMed

29.

Falcone F, Breda E, Ferrandina G, et al. Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database. Gynecol Oncol. 2021;161(3):825–31. https://doi.org/10.1016/j.ygyno.2021.03.023.CrossRefPubMed

30.

Wang P, Fang L. Salpingo-oophorectomy versus cystectomy in patients with borderline ovarian tumors: a systemic review and meta-analysis on postoperative recurrence and fertility. World J Surg Oncol. 2021;19:132. https://doi.org/10.1186/s12957-021-02241-2.CrossRefPubMedPubMedCentral

31.

Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril. 2001;75(1):92–6. https://doi.org/10.1016/S0015-0282(00)01633-2.CrossRefPubMed

32.

Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013;19(2):151–66. https://doi.org/10.1093/humupd/dms047.CrossRefPubMed

33.

Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27(3):281–92. https://doi.org/10.1097/00000478-200303000-00001.CrossRefPubMed

34.

Gauroy E, Larouzée E, Chéreau E, et al. Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Diagnosis and Management of Recurrent Borderline Ovarian Tumours. Gynecol Obstet Fertil Senol. 2020;48(3):314–21. https://doi.org/10.1016/j.gofs.2020.01.019.CrossRefPubMed

35.

De Decker K, Jaroch KH, Edens MA, et al. Frozen section diagnosis of borderline ovarian tumors with suspicious features of invasive cancer is a devil’s dilemma for the surgeon: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2021;100(8):1369–76. https://doi.org/10.1111/aogs.14105.CrossRefPubMed

36.

Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2017;41:49–59. https://doi.org/10.1016/j.bpobgyn.2016.09.012.CrossRefPubMed

37.

Song T, Choi CH, Kim HJ, et al. Accuracy of frozen section diagnosis of borderline ovarian tumors. Gynecol Oncol. 2011;122(1):127–31. https://doi.org/10.1016/j.ygyno.2011.03.021.CrossRefPubMed

38.

Tsai HW, Ko CC, Yeh CC, et al. Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors. J Chin Med Assoc. 2011;74(6):250–4. https://doi.org/10.1016/j.jcma.2011.04.003.CrossRefPubMed

Title: Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study
Authors: Jiayuan Zhao
Dan Wang
Ruojiao Wang
Yonglan He
Congwei Jia
Lingya Pan
Shuiqing Ma
Ming Wu
Weidi Wang
Xinghan Cheng
Junjun Yang
Yang Xiang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Cystectomy
Fertility
Salpingo-Oophorectomy
Published in: Journal of Ovarian Research / Issue 1/2024
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-024-01409-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance

Controlled ovarian stimulation in cancer patients under 18 years old; a case series

Loss of Calponin 2 causes premature ovarian insufficiency in mice

Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1

Do we overlook predictive factors in Poseidon 1 patients? A retrospective analysis co-evaluating antral follicle counts & diameters

Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study